Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose with this study is to describe in detail the control or lack of control of asthma, based on two different dosing strategies, regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed, or maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed.
The purpose with this study is to describe in detail the control or lack of control of asthma, based on two different dosing strategies. No therapy intervention is made with existing prescribed medications (SERETIDE or SYMBICORT), but evaluations outside standard care is made by evluations with diary cards, questionnaires, PEF evaluations and spirometry which is regarded as the intervention by the Swedish Authorities.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Stable dosing with SERETIDE, short acting B-2agonist as needed | Experimental | Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed |
|
| Maintenance treatment with SYMBICORT and SYMBICORT as needed | Experimental | Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Spirometry, PEF measurements and diary cards to evaluate control of Asthma | Other | No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires |
| Measure | Description | Time Frame |
|---|---|---|
| asthma control based on GINA guidelines from 2007. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life, Health economics and exacerbations | 3 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Stockholm | SE-171 77 | Sweden |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jul 23, 2017 | |
| Reset | Jan 2, 2018 | |
| Release | Jan 8, 2018 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Unrelease | Aug 15, 2018 |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jul 23, 2017 | Jan 2, 2018 | |||
| Jan 8, 2018 | Aug 15, 2018 |
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012130 | Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
Not provided
Not provided